KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 1 Not yet finished but already full! 3 Completed 1

New drug targets tough cancers in Gene-Mutated patients

Disease control Completed

This study tested a drug called GFH925 in 334 people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal was to see if the drug is safe and can shrink tumors or slow their growth. It is not a cure, but aims to control the disease for as long as po…

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control

Last updated Jun 15, 2026 19:09 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New drug targets tough cancers in Gene-Mutated patients